Anteris是一家专注于主动脉狭窄患者的结构性心脏公司。其主导产品DurAVR经导管心脏瓣膜(THV)系统由单件式仿生瓣膜组成，迄今为止，美国、加拿大和欧洲共有73名患者接受了DurAVR THV系统的治疗。The company plans to issue 14.8 million stocks at a price of $6.78 per share to raise $0.1 billion in funding.
According to Zhithong Finance APP, Anteris Technologies, an artificial heart valve manufacturer in Australia, announced its IPO terms on Monday. The company plans to issue 14.8 million stocks at a price of $6.78 per share to raise $0.1 billion in funding. At the proposed price, Anteris Technologies' market cap will reach $0.244 billion.
The company's stocks are currently listed on the Australian Stock Exchange under the code "AVR". The pricing of $6.78 corresponds to its closing price on December 5 on the Australian Stock Exchange.
Anteris is a structural heart company focused on patients with aortic stenosis. Its leading product, the DurAVR transcatheter heart valve (THV) system, consists of a single-piece biomimetic valve. So far, 73 patients have received treatment with the DurAVR THV system in the USA, Canada, and Europe.
The company was founded in 1999, and its revenue for the 12 months ending September 30, 2024, is $3 million. The company plans to list on nasdaq, with the stock code AVR. Anteris confidentially submitted its application on February 14, 2024. TD cowen inc 7.75% senior notes due 15/06/33 usd25, Barclays and Cantor Fitzgerald are the joint bookrunners for this trade.
